AC105 improved motor function after spinal cord injury in preclinical studies ARDSLEY, N.Y., Sep 25, 2013 (BUSINESS WIRE) — Acorda Therapeutics, Inc. /quotes/zigman/91130/quotes/nls/acor ACOR +1.38% today announced that the first patient has been enrolled in a trial of AC105, its proprietary magnesium formulation for the treatment of spinal cord injury (SCI). This Phase 2 trial will evaluate the safety and tolerability of the drug in people with traumatic SCI, and also incorporates several exploratory efficacy measures…
That All May Walk Again!